Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Dual-Targeted 68Ga-FAPI-PSMA PET/CT for the Diagnosis and Staging of Solid Tumors

NCT07639801 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT07639801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07639801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Dual-Targeted 68Ga-FAPI-PSMA PET/CT for the Diagnosis and Staging of Solid Tumors
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Not applicable
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
December 31, 2026
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, fapi, hepatocellular carcinoma, ovarian cancer, prostate cancer, psma, solid tumors